ONCT - Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02 revenue of $0.2M misses by $0.26M
- Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q2 GAAP EPS of -$0.23 beats by $0.02 .
- Revenue of $0.2M (-77.3% Y/Y) misses by $0.26M .
- Extended cash runway guidance to fund operations into the first half of 2024 with $78.9 million in cash and cash equivalents and no debt as of June 30, 2022
For further details see:
Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M